छोड़कर सामग्री पर जाएँ

Concord Biotech stock gains 3% as Kotak and Antique Broking issue positive coverage

  • द्वारा
  • Latest News

Kotak Institutional Equities based on strong discounted cash flows and the company’s expertise in high entry barrier fermentation active pharmaceutical ingredients (API) segment sees a 15 percent upside potential from the current price levels.

Top 100 Best Sellers

Read More

​ Kotak Institutional Equities based on strong discounted cash flows and the company’s expertise in high entry barrier fermentation active pharmaceutical ingredients (API) segment sees a 15 percent upside potential from the current price levels. Kotak Institutional Equities based on strong discounted cash flows and the company’s expertise in high entry barrier fermentation active pharmaceutical ingredients (API) segment sees a 15 percent upside potential from the current price levels.  Moneycontrol Latest News Read More  

प्रातिक्रिया दे

आपका ईमेल पता प्रकाशित नहीं किया जाएगा. आवश्यक फ़ील्ड चिह्नित हैं *

hi_INहिन्दी
en_USEnglish hi_INहिन्दी